Since platelets express transmembrane-SR-PSOX/CXCL16 [9] and may contribute to serum sCXCL16, we have extended these clinical findings by exploring the relevance of platelet SR-PSOX/CXCL16 and CXCR6 in influencing thrombotic potential and prognosis among CAD patients over a three-year follow-up period. Here, CXCR6 is linked to coronary artery disorder.